Segment Information (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) segment	Sep. 30, 2022 USD ($)
Segment Reporting Information [Line Items]
Number of reportable segments | segment			2
Total revenue	$ 9,282	$ 19,018	$ 13,679	$ 21,999
Cost of revenue	848	923	2,698	3,146
Research and development	23,876	23,656	71,738	56,741
General and administrative	7,091	5,813	24,198	17,987
Licensing	7,344	7,300	8,955	7,300
Revaluation of contingent consideration	1,700	2,200	(600)	(2,400)
Loss from operations	(31,577)	(20,874)	(93,310)	(60,775)
Operating Segments | Dermatology Therapeutics Segment
Segment Reporting Information [Line Items]
Total revenue	8,577	17,928	11,210	18,469
Research and development	24,110	23,863	72,490	57,329
Licensing	7,344	7,300	8,955	7,300
Revaluation of contingent consideration	1,700	2,200	(600)	(2,400)
Loss from operations	(24,577)	(15,435)	(69,635)	(43,760)
Operating Segments | Contract Research Segment
Segment Reporting Information [Line Items]
Total revenue	4,817	4,299	14,591	12,795
Cost of revenue	4,726	3,925	14,068	11,823
General and administrative	1,174	875	3,490	2,570
Loss from operations	(1,083)	(501)	(2,967)	(1,598)
Corporate and Other
Segment Reporting Information [Line Items]
Total revenue	(4,112)	(3,209)	(12,122)	(9,265)
Cost of revenue	(3,878)	(3,002)	(11,370)	(8,677)
Research and development	(234)	(207)	(752)	(588)
General and administrative	5,917	4,938	20,708	15,417
Loss from operations	(5,917)	(4,938)	(20,708)	(15,417)
Intersegment Eliminations | Contract Research Segment
Segment Reporting Information [Line Items]
Total revenue	$ 4,100	$ 3,200	$ 12,100	$ 9,300